Reflux Oesophagitis
8
Pipeline Programs
2
Companies
4
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
8
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Ferring PharmaceuticalsArgentina - Buenos Aires
4 programs4
YF476Phase 11 trial
YF476Phase 11 trial
YF476Phase 11 trial
YF476Phase 11 trial
Active Trials
+1 more trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Ferring PharmaceuticalsYF476
Ferring PharmaceuticalsYF476
Ferring PharmaceuticalsYF476
Ferring PharmaceuticalsYF476
Clinical Trials (4)
Total enrollment: 135 patients across 4 trials
Effect of 5, 10 or 25 mg of YF476 Daily for 14 Days on Stomach Acidity in Healthy Volunteers
Start: Apr 1997Est. completion: Jun 199749 patients
Phase 1Completed
Effect of Repeated Doses of YF476, Omeprazole and Placebo on Stomach Acidity in Healthy Volunteers
Start: Aug 1996Est. completion: Oct 199649 patients
Phase 1Completed
Effect of Single Doses of YF476 on Stomach Acidity Compared With Ranitidine and Placebo in Fasted and Fed States
Start: Jul 1996Est. completion: Aug 199622 patients
Phase 1Completed
Safety, Tolerability and Pharmacokinetics of Single Rising Doses of YF476, a Gastrin Antagonist, in Healthy Men
Start: May 1996Est. completion: Jun 199615 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space